Multiple oral and intravenous disease-modifying therapies (DMTs) have been approved for the treatment of relapsing-remitting multiple sclerosis (RRMS), and all have demonstrated efficacy in reducing both clinical relapses and development of new MRI-detected lesions. Despite this efficacy, individual patients may experience some breakthrough disease and need to consider changing therapies.
Dr Clyde Markowitz, director of the Penn Comprehensive Multiple Sclerosis Center in Philadelphia, Pennsylvania, discusses considerations for determining breakthrough disease in patients with both new and established RRMS. He also reports on the current approach to changing disease-modifying therapies and the importance of the shared–decision-making model.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Managing Progression in Relapsing-Remitting Multiple Sclerosis - Medscape - Jun 04, 2020.
Comments